title: Novel targeted therapies for the treatment of metastatic melanoma.
abstract: The National Comprehensive Cancer Network guidelines for the treatment of stage IV metastatic melanoma state that clinical trials should be the preferred treatment option for these patients; therefore, clinical trials for these patients are the "standard of care." Our greater understanding of the molecular biology behind the development of melanoma has guided much of the translational research in this disease and has led to the development of novel targeted therapies. Specifically, advancement in our knowledge of alterations in signal transduction pathways in melanoma has led to the rapid development of a number of pharmacologic agents that inhibit these pathways. This review will discuss changes in signal transduction pathways involved in melanoma, specifically, activated mitogen-activated protein kinase, activated PI3 kinase, and inactivated p53/Rb pathways. This article will also review new targeted therapy in the context of the molecular biology of melanoma.
authors: Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.
authors: Ragini
authors: R
authors: Kudchadkar
references: Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s
references: 16609062
references: Curr Opin Oncol. 2008 Mar;20(2):183-9
references: 18300768
references: Science. 2005 Feb 4;307(5710):720-4
references: 15618488
references: Br J Cancer. 2006 Sep 4;95(5):581-6
references: 16880785
references: J Med Genet. 2007 Feb;44(2):99-106
references: 16905682
references: Cancer Res. 2004 Jul 15;64(14):4912-8
references: 15256463
references: Ann Oncol. 2008 Mar;19(3):590-4
references: 18037622
references: Mol Cancer Ther. 2003 Nov;2(11):1093-103
references: 14617782
references: Nat Med. 1998 Feb;4(2):232-4
references: 9461199
references: Physiol Rev. 2004 Oct;84(4):1155-228
references: 15383650
references: J Clin Oncol. 1999 Jul;17(7):2105-16
references: 10561265
references: J Clin Oncol. 2008 May 1;26(13):2178-85
references: 18445842
references: Mayo Clin Proc. 2008 Jul;83(7):825-46
references: 18613999
references: Clin Cancer Res. 2006 Aug 1;12(15):4619-27
references: 16899610
references: Cancer Res. 2003 Jun 1;63(11):2881-90
references: 12782594
references: J Clin Oncol. 2006 Sep 10;24(26):4340-6
references: 16908931
references: Invest New Drugs. 2005 Dec;23(6):569-75
references: 16034524
references: J Biol Chem. 1982 Dec 25;257(24):14949-59
references: 7174676
references: Oncogene. 2004 Nov 4;23(52):8509-19
references: 15378016
references: Invest New Drugs. 2004 Aug;22(3):315-22
references: 15122079
references: Cancer. 2003 Aug 15;98(4):798-804
references: 12910525
references: Cancer Treat Rep. 1976 Feb;60(2):193-8
references: 769973
references: Cancer Cell. 2003 Oct;4(4):257-62
references: 14585353
references: Clin Exp Metastasis. 2003;20(6):531-9
references: 14598887
references: Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38
references: 18353141
references: J Clin Oncol. 2009 Jun 10;27(17):2823-30
references: 19349552
references: Cancer Res. 2001 Oct 1;61(19):7318-24
references: 11585772
references: Pigment Cell Res. 2001 Dec;14(6):456-65
references: 11775058
references: Br J Cancer. 2008 Sep 2;99(5):734-40
references: 18728664
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: Ann N Y Acad Sci. 2005 Nov;1059:16-25
references: 16382039
references: J Invest Dermatol. 1994 Nov;103(5 Suppl):112S-116S
references: 7963671
references: Cancer Res. 2000 Apr 1;60(7):1800-4
references: 10766161
references: Cancer Res. 2004 Oct 1;64(19):7002-10
references: 15466193
references: J Clin Oncol. 2006 Oct 10;24(29):4738-45
references: 16966688
references: J Leukoc Biol. 2003 Jun;73(6):689-701
references: 12773501
references: Clin Cancer Res. 2008 Aug 1;14(15):4836-42
references: 18676756
references: Hum Mutat. 2007 Jun;28(6):622-9
references: 17311302
references: J Clin Oncol. 2009 Nov 10;27(32):5452-8
references: 19826135
references: J Mol Histol. 2004 Mar;35(3):309-18
references: 15339050
references: N Engl J Med. 2005 Nov 17;353(20):2135-47
references: 16291983
references: Nat Med. 2000 Sep;6(9):1029-35
references: 10973324
references: Cancer. 2005 Sep 1;104(5):1045-8
references: 16007689
references: J Invest Dermatol. 2006 Feb;126(2):422-31
references: 16374457
references: Nature. 2007 Feb 22;445(7130):851-7
references: 17314971
references: J Pharmacol Exp Ther. 2000 Oct;295(1):139-45
references: 10991971
references: Cancer Res. 2006 Feb 1;66(3):1611-9
references: 16452220
references: J Invest Dermatol. 1994 Mar;102(3):285-90
references: 8120410
references: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references: 15961763
references: Cancer. 2005 Jun 15;103(12):2584-9
references: 15887220
references: Genes Dev. 2000 Oct 1;14(19):2501-14
references: 11018017
references: Cancer Res. 1994 Dec 1;54(23):6041-4
references: 7954442
references: Clin Cancer Res. 2010 Mar 15;16(6):1924-37
references: 20215549